Understanding the Links Between Endometrial, Breast, and Ovarian Cancer

By Dr. Sharyn Lewin

Endometrial cancer (cancer of the uterine lining) doesn’t always get the same attention as breast or ovarian cancer, but for many women and families already navigating hereditary cancer risk, it’s an important piece of the puzzle. Endometrial, breast, and ovarian cancers are connected in several important ways: through shared genetic mutations, overlapping hormonal pathways, and sometimes through the very treatments used to treat one cancer that can raise the risk of another. Understanding these connections can help you and your care team make more informed decisions about screening, treatment, and long-term follow-up.

The Genetic Connections

Lynch Syndrome: Lynch syndrome, caused by inherited mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS2, or EPCAM), is best known for raising colorectal cancer risk, but for women, endometrial cancer is often the first cancer to appear, sometimes preceding a colorectal cancer diagnosis by years. Lynch syndrome also meaningfully increases ovarian cancer risk. Because Lynch syndrome runs in families and can appear in relatives with what looks like a mix of “different” cancers, such as colon, uterine, and ovarian cancers, a personal or family history of any of these should prompt a conversation about genetic counseling and testing.

BRCA1 and BRCA2: BRCA mutations are most strongly linked to breast and ovarian cancer, but research has identified a modestly increased risk of a more aggressive endometrial cancer subtype, serous/high-grade endometrial carcinoma, particularly in BRCA1 carriers. This risk is much smaller than the breast and ovarian cancer risk associated with BRCA mutations, but it’s part of why some BRCA carriers and their surgeons discuss removing the uterus (not just the ovaries and fallopian tubes) at the time of risk-reducing surgery, especially if tamoxifen is or will be part of treatment.

Other hereditary syndromes: Less commonly, PTEN hamartoma tumor syndrome (Cowden syndrome) raises the risk of endometrial, breast, and other cancers together, underscoring that “one gene, one cancer” is rarely how hereditary risk actually works.

The Hormonal Connections

Beyond genetics, breast, ovarian, and endometrial cancers share hormonal biology. Estrogen exposure, whether from the body’s own hormones, obesity (fat tissue produces estrogen), infertility, or hormone therapy, plays a role in the development of both estrogen-receptor-positive breast cancer and the most common type of endometrial cancer (endometrioid). This overlap becomes especially relevant during breast cancer treatment. Tamoxifen, a cornerstone therapy for hormone-receptor-positive breast cancer, acts as an anti-estrogen in breast tissue but can act like estrogen in the uterine lining. This is why tamoxifen use is associated with a small but real increased risk of endometrial cancer and endometrial changes such as polyps or hyperplasia. It’s a classic example of a treatment decision for one cancer having downstream implications for another organ.

How These Connections Shape Treatment Decisions

For women with a known or suspected hereditary risk, or a personal history of breast cancer: Genetic counseling and testing can clarify whether Lynch syndrome, a BRCA mutation, or another hereditary syndrome is present, which in turn shapes decisions about surveillance, prevention, and family planning.

Timing of risk-reducing surgery: For BRCA carriers undergoing risk-reducing removal of the ovaries and fallopian tubes, some surgical teams discuss also removing the uterus, particularly if tamoxifen use is anticipated or ongoing.

Monitoring during tamoxifen therapy: Women on tamoxifen are typically counseled to report any abnormal uterine bleeding promptly, since this is the most common early sign of endometrial changes. Routine ultrasound screening isn’t generally recommended for women without symptoms, but any bleeding after menopause or irregular bleeding before menopause warrants evaluation.

Lynch syndrome surveillance: For women with Lynch syndrome, discussions often include annual endometrial biopsies or ultrasounds starting in the 30s, and consideration of risk-reducing hysterectomy (often paired with removal of the ovaries and fallopian tubes) once childbearing is complete.

Systemic therapy choices: Knowing a patient’s genetic status can influence which treatments are used. For instance, tumors with mismatch repair deficiency (a hallmark of Lynch syndrome) may respond particularly well to immunotherapy, an option increasingly used in endometrial cancer treatment.

Long-Term Health Considerations: Surviving one cancer while carrying elevated risk for others means that long-term care needs to look beyond the original diagnosis. Coordinated, lifelong follow-up across gynecologic oncology, breast oncology, and genetics teams helps ensure no risk is overlooked.

Surgical menopause effects: Risk-reducing removal of the ovaries, especially at a younger age, brings on early menopause, with implications for bone health, cardiovascular health, and quality of life that deserve dedicated discussion and management.

Family communication: Because these cancers can cluster in families through shared genetics, a diagnosis in one family member is often a signal for others to consider testing and earlier or more frequent screening.

Weight: Metabolic health and lifestyle factors that influence estrogen levels are relevant to reducing endometrial (and breast) cancer risk over the long run, alongside, not instead of, genetic and medical management.

The Bottom Line

Endometrial cancer doesn’t exist in isolation from breast and ovarian cancer. Shared genetic syndromes like Lynch syndrome and BRCA mutations, overlapping hormonal drivers, and the real-world effects of treatments like tamoxifen all mean that a fuller picture of risk, and a coordinated care team, matters. If you or someone in your family has had breast, ovarian, or endometrial cancer, or if abnormal uterine bleeding occurs during or after breast cancer treatment, a conversation with your doctor about genetic counseling and appropriate surveillance is a reasonable and important next step.

This post is intended for general educational purposes and is not a substitute for individualized medical advice. Please speak with your healthcare provider or a genetic counselor about what these connections may mean for your personal or family history.

Sharyn N. Lewin, MD, FACS, FACOG, is recognized both nationally and internationally for her acumen in performing laparoscopic, robotic, and open surgery to treat complex gynecologic cancers and related malignancies of the upper abdomen and pelvic/colorectal areas. Board-certified in obstetrics/gynecology and gynecologic oncology, Dr. Lewin provides surgery and chemotherapy (including hyperthermic intraperitoneal chemotherapy [HIPEC]), thus enabling her to offer continuous care over each patient’s lifetime.

Dr. Lewin earned her medical doctorate at the University of Kansas School of Medicine, where she was honored with the Russell F. Holcomb Award for Outstanding Performance in Obstetrics & Gynecology and named University Scholar for Outstanding Achievement. She completed her obstetrics/gynecology residency at Washington University School of Medicine/Barnes Jewish Hospital in St. Louis and was named to the Alpha Omega Alpha Honor Society. During her residency and four-year gynecologic oncology fellowship at Memorial Sloan Kettering Cancer Center, she received numerous academic, research, and teaching awards, including the Outstanding Resident Award for Teaching Excellence, the Galloway Fellowship, and the Society of Gynecologic Oncologists’ 2004 President’s Award. Prior to joining Holy Name, she was on the faculty of the Columbia University College of Physicians and Surgeon for five years and was the first Medical Director of the New York-Presbyterian Hospital Woman to Woman Program. She received New York-Presbyterian Hospital’s 2010 Physician of the Year Award and was honored by Gilda’s Club New York City at its 6th Annual Benefit Luncheon in 2013. 

An authority on hereditary breast and ovarian cancer syndrome (which increases one’s risk for ovarian and other cancers among those who carry the BRCA breast cancer genes), Dr. Lewin has presented at national medical conventions. Her research interests include novel chemotherapeutic agents for ovarian cancer, including HIPEC and immunotherapy; quality-of-life studies; and patient outcomes following the use of integrative therapies during treatment.  She is currently an Assistant Clinical Professor in the Icahn School of Medicine at Mount Sinai Hospital in New York.

As President and Executive Director of the non-profit The Lewin Fund to Fight Women’s Cancers®, Dr. Lewin is dedicated to eliminating medical, economic, and psychosocial challenges faced by women with cancer. She serves on the prestigious Gynecologic Oncology Group (GOG) Partners Investigative Council, offering key clinical trials to our patients. Dr. Lewin has received numerous awards and accolades including, the Teaneck Chamber of Commerce’s Physician of the Year Award, the Russ Berrie Making a Difference Award, Honoring NJ Heroes, MarquisWho’s Who, and had been listed as a Top Doctor, NY Magazine and NJ 201 Magazine, since 2015.